Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of tivantinib (ARQ 197) in advanced hepatocellular carcinoma
jRCT2080221860Phase 1
- Sponsor
- Kyowa Kirin
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tivantinib in hepatocellular carcinoma (HCC), sponsored by Kyowa Kirin.
02
Drugs
tivantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080221860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221860.